We are extremely delighted to announce that we successfully submitted our DCP procedure for Liraglutide 6mg/ml pre-filled pen on Friday 29th October, which has been developed in close collaboration with one of our strategic partners.
Our product is a generic and bioequivalent version of Victoza® pre-filled pen which is a peptide drug indicated for the treatment of type2 diabetes. The brand is currently selling over $5 billion globally as reported by IQVIA.
We believe that we are among the first companies to file a DCP procedure for this product and with this achievement, we believe we can be among the first companies to launch a generic version in all our key markets.
We will now move full steam ahead to ensure a Day-1 Europe launch. By achieving this major milestone we believe our Liraglutide development will become a true landmark of our ability to create a high-value portfolio containing complex products including peptide injections.
On top of this, Adalvo is offering another 7 complex peptide projects to its partners and patients with a combined global market size exceeding $10bn.